Detected ·
Allotera Therapeutics
$35M—
Allotera Therapeutics (formerly Wugen) closed a $35M financing round, bringing total Series C capital raised to $150M to support their global T-RRex clinical trial of Soficabtagene Geleucel (Sofi-cel), a CD7-targeted CAR-T cell therapy for relapsed or refractory T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma.
- Website
- www.wugen.com
- linkedin.com/company/wugen
- Amount
- $35 000 000 USD
- Stage
- —
- Event
- Funding round
- Detected
- 2026-07-08 16:12:40 UTC
- Signal ID
- 19512b10-8f03-442f-b91b-8ff0e770aa96
As the API returns it
{
"id": "19512b10-8f03-442f-b91b-8ff0e770aa96",
"created_at": "2026-07-08T16:12:40.068996Z",
"company_name": "Allotera Therapeutics",
"company_website_url": "www.wugen.com",
"company_linkedin_url": "https://www.linkedin.com/company/wugen",
"event_type": "funding",
"funding_amount": 35000000,
"funding_currency": "USD",
"funding_stage": null,
"message": "*Allotera Therapeutics (formerly Wugen) closed a $35M financing round, bringing total Series C capital raised to $150M to support their global T-RRex clinical trial of Soficabtagene Geleucel (Sofi-cel), a CD7-targeted CAR-T cell therapy for relapsed or refractory T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma.*"
}